Section Arrow
SAGE.NASDAQ
- Sage Therapeutics
Quotes are at least 15-min delayed:2024/06/24 08:13 EDT
Last
 11.09
+0.42 (+3.94%)
Day High 
11.32 
Prev. Close
10.67 
1-M High
12.38 
Volume 
4.29M 
Bid
10.41
Ask
11.95
Day Low
10.5 
Open
10.72 
1-M Low
9.76 
Market Cap 
642.14M 
Currency USD 
P/E -- 
%Yield
10-SMA 10.99 
20-SMA 11.16 
50-SMA 12.46 
52-W High 56.37 
52-W Low 9.76 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.39/-5.72
Enterprise Value
642.14M
Balance Sheet
Book Value Per Share
11.73
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
86.46M
Operating Revenue Per Share
0.19
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MBIOMustang Bio0.5594-0.0011-0.20%-- 
DNAGinkgo Bioworks Holdings0.4244+0.0157+3.84%-- 
KTRAKintara Therapeutics0.2472-0.0277-10.08%-- 
BMRNBioMarin Pharmaceutical83.72-0.99-1.17%79.92PE
QLGNQualigen Therapeutics0.222+0.0449+25.35%-- 
Quotes are at least 15-min delayed:2024/06/24 08:13 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.